Innovative Medicine
Backed by the Power of
BioXcel Therapeutics, Inc. is a
biopharmaceutical company developing transformative medicines in neuroscience and immuno-oncology utilizing artificial intelligence approaches.
Innovative Medicine
Backed by the
Power of
BioXcel Therapeutics, Inc., a clinical-stage biopharmaceutical company developing transformative medicines in neuroscience and immuno-oncology utilizing artificial intelligence, or AI, techniques.
Innovative Medicine
Backed by the Power of
BioXcel Therapeutics, Inc., a clinical-stage biopharmaceutical company developing transformative medicines in neuroscience and immuno-oncology utilizing artificial intelligence, or AI, techniques.
Our Approach to Drug Development
- Optimizes R&D Economics
- Shortens Development Timelines
- Increases Probability of Success
AI-based Drug Development
Our neuroscience and immuno-oncology franchises utilize our AI
approach to drug identification and development
Neuroscience
Immuno-Oncology
Aug 14, 2023
BioXcel Therapeutics Reports Second Quarter 2023 Financial Results and Announces Strategic ReprioritizationVIEW RELEASE
Jul 31, 2023
BioXcel Therapeutics to Report Second Quarter 2023 Financial Results on August 14, 2023VIEW RELEASE
Jun 29, 2023
BioXcel Therapeutics Announces Positive Topline Results From TRANQUILITY II Phase 3 Trial of BXCL501 for Acute Treatment of Alzheimer’s Disease-Related AgitationVIEW RELEASE
Stock Information
BioXcel Therapeutics, Inc.
Sep 20, 2023 04:00 PM
MARKET/SYMBOL
Nasdaq:
BTAI
PRICE
3.02
CHANGE
0 (0%)
